In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Hold rating on Proteostasis Therapeutics Inc (NASDAQ: PTI), with a price target of $4. The company’s shares closed yesterday at $2.45, close to its 52-week low of $1.41.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.3% and a 55.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
Proteostasis Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
Based on Proteostasis Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $11.03 million. In comparison, last year the company had a GAAP net loss of $16.96 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Proteostasis Therapeutics, Inc. engages in the research, development, and market of pharmaceutical products. Its medicines intend to treat cystic fibrosis, protein conformational and neurodegenerative diseases.
